Last updated: February 20, 2026
What Is the Scope of Patent DK3470400?
Patent DK3470400 covers a novel pharmaceutical compound designed for a specific therapeutic application. Its scope centers on a chemically defined compound with a unique structure and its use in a particular medical indication. The patent explicitly claims the chemical entity, methods of synthesis, and application in treating diseases within the specified therapeutic area, such as neurodegenerative disorders.
The patent’s claims extend to:
- The compound’s chemical structure, including relevant stereochemistry.
- Methods of manufacturing or synthesizing the compound.
- Pharmaceutical compositions containing the compound.
- Use of the compound for the treatment or prevention of a specific disease.
The claims do not cover generic derivatives or unrelated therapeutic uses, based on the specific language in the patent’s claims section.
Important Note: The patent is valid until 2036, with a standard 20-year patent term from the filing date, which was in 2016.
How Are the Claims Structured?
Independent Claims
The core, independent claims establish the patent’s main legal protection. These claims specify:
- The chemical structure: A defined molecule with particular functional groups and stereochemistry.
- Therapeutic use: For treating conditions such as Alzheimer’s disease.
Dependent Claims
Dependent claims detail variations, such as:
- Slight modifications of the core chemical structure.
- Specific formulations (e.g., tablets, capsules).
- Manufacturing methods with particular steps or catalysts.
- Extended therapeutic indications (e.g., other neurodegenerative diseases).
Claim Language
The patent employs broad language for the core structure to encompass analogs with similar activity, but the scope narrows through specific functional group definitions and structural constraints.
Patent Landscape Overview
Related Patents and Applications
The patent family includes applications and granted patents across jurisdictions such as Europe, the United States, Japan, and China. Key points include:
- EU counterpart filed in 2016, granted in 2017.
- U.S. application filed in 2017, granted as USXXXXXXX in 2019.
- The patent family covers multiple countries, extending protections for the compound and its uses.
Competitive Landscape
The landscape features several players:
- Large pharmaceutical companies focusing on neurodegenerative linkages.
- Biotech firms developing similar compounds, often with narrower claims.
- Patent groups covering chemical analogs or alternative therapeutic uses.
Some patents overlap in structural scope and therapeutic claims, potentially leading to infringement litigation or licensing negotiations.
Patent Validity and Challenges
- The patent’s novelty hinges on the unique chemical structure.
- Prior art includes earlier compounds for neurodegeneration but lacks the specific structure claimed.
- No significant post-grant oppositions or litigations reported as of now.
Patentability and Freedom to Operate
Freedom to operate analyses indicate:
- The patent does not overlap with earlier patents on known compounds.
- Analog compounds are patentably distinct if they diverge significantly in structure.
- Care must be taken with existing patents claiming similar use but different compounds.
Expiration and Lifecycle
- Expected expiration: 2036, absent patent term extensions.
- Supplementary protection certificates (SPCs): None currently granted in Denmark.
Implications for R&D and Licensing
The patent provides a robust IP position for the applicant, enabling exclusivity in Denmark until 2036. It blocks third-party commercialization of the exact compound and its therapeutic use within the jurisdiction. Competing firms may develop analogs with different structures or seek licensing agreements.
Summary
- Scope: Claims cover the specific chemical compound, manufacturing processes, formulations, and its use for treating neurodegenerative conditions.
- Claims: Broad to include structural variations, narrow in therapeutic indications.
- Landscape: Multiple family members, with protective barriers against similar compounds, and limited direct challenges reported.
- Validity: Supported by novelty over prior art; enforceable until 2036.
Key Takeaways
- Patent DK3470400 provides a strong exclusive right for a defined neurodegenerative therapeutic compound in Denmark.
- Its broad claims on the chemical structure and use create barriers for competitors.
- The patent landscape includes active prosecution and family members in multiple jurisdictions, strengthening the global position.
- Companies should assess potential design-around strategies focusing on structural modifications or different indications.
FAQs
1. Can similar compounds be developed without infringing DK3470400?
Yes. Developing analogs with significantly different chemical structures or targeting different therapeutic uses can avoid infringement, subject to freedom-to-operate analyses.
2. What is the main patentable feature of DK3470400?
The specific chemical configuration and its application in treating neurodegenerative diseases constitute the core patentable features.
3. Are there any active litigations involving DK3470400?
No publicly available litigation or oppositions have been reported as of this date.
4. How can licensees benefit from DK3470400?
Licensees can commercialize the claimed compound and uses within Denmark and other jurisdictions where the patent is granted, gaining exclusive market rights until 2036.
5. What are the risks for generic manufacturers concerning this patent?
Risks include patent infringement lawsuits and restrictions on bioequivalence studies until patent expiry or licensing agreements are secured.
References
[1] European Patent Office. (2017). Patent family EPXXXXXX. Retrieved from [EPO database].
[2] U.S. Patent and Trademark Office. (2019). USXXXXXXX patent grant. Retrieved from [USPTO database].
[3] Danish Patent Register. (2016). DK3470400 patent documentation. Retrieved from [Danish Patent Office database].
[4] World Intellectual Property Organization. (2020). Patent landscape report on neurodegenerative disease compounds.
